Active substanceHydrocortisoneHydrocortisone
Similar drugsTo uncover
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment d / eye 
  • Hydrocortisone
    ointment locally 
  • Hydrocortisone
    ointment d / eye 
    SYNTHESIS, OJSC     Russia
  • Hydrocortisone
    suspension w / m in / Sust. 
    FARMAK, JSC     Ukraine
  • Hydrocortisone
    ointment d / eye 
    VALEANT, LLC     Russia
  • Hydrocortisone
    ointment externally 
    AKRIKHIN HFK, JSC     Russia
  • Hydrocortisone
    ointment externally 
    SYNTHESIS, OJSC     Russia
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment externally 
    BIOSINTEZ, PAO     Russia
  • Hydrocortisone
    ointment externally 
    NIZHFARM, JSC     Russia
  • Hydrocortisone
    ointment externally 
    ATOLL, LLC     Russia
  • Hydrocortisone-POS®
    ointment d / eye 
  • Cortef®
    pills inwards 
    Pfizer Inc.     USA
  • Laticort®
    ointment externally 
    VALEANT, LLC     Russia
  • Laticort®
    cream externally 
    VALEANT, LLC     Russia
  • Laticort®
    solution externally 
    VALEANT, LLC     Russia
  • Lokoid®
    cream externally 
    Astellas Farma Europe BV     Netherlands
  • Lokoid®
    ointment externally 
  • Lokoid Creole®
    emulsion externally 
    Astellas Farma Europe BV     Netherlands
  • Lokoid Lipocream®
    cream externally 
    Astellas Farma Europe BV     Netherlands
  • Solu-Cortef®
    lyophilizate w / m in / in 
  • Dosage form: & nbspointment for external use
    Composition:

    in 1 g of ointment:

    Active substance: hydrocortisone butyrate -1 mg.

    Excipient: white petrolatum up to 1 g.

    Description:Almost colorless, translucent fatty mass.
    Pharmacotherapeutic group:Glucocorticosteroid for topical application
    ATX: & nbsp

    S.01.B.A.02   Hydrocortisone

    H.02.A.B.09   Hydrocortisone

    D.07.A.A.02   Hydrocortisone

    Pharmacodynamics:

    Laticort® is an active, synthetic, non-halogenated glucocorticosteroid drug for topical use. Has a quick anti-inflammatory, anti-decongestant, antipruritic and anti-allergic action. Due to local vasoconstrictive action reduces exudative reactions.

    The use of ointment in recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system.

    Pharmacokinetics:

    Suction

    After application, the active substance accumulates in the epidermis, mainly in the granular layer.

    Metabolism

    Hydrocortisone butyrate, absorbed through the skin, is metabolized to hydrocortisone and other metabolites directly in the epidermis and subsequently, in the liver.

    Excretion

    Metabolites and a small part of unchanged hydrocortisone butyrate is excreted by the kidneys and with bile.

    Indications:

    Uninfected, sensitive to local glucocorticosteroids, skin diseases that occur with excessive keratinization:

    - seborrheic dermatitis;

    - atopic dermatitis; erythroderma;

    - contact eczema;

    - psoriasis;

    - red flat herpes.

    Insect bites.

    Contraindications:

    - hypersensitivity to the components of the drug;

    - bacterial, viral and fungal skin infections;

    - acne vulgaris, rosacea;

    - perioral dermatitis;

    - postvaccination period;

    - violation of the integrity of the skin (wounds, ulcers);

    - skin tumors;

    - tuberculosis or syphilitic skin lesions;

    - children age up to 6 months, with itching in the anus - up to 12 years.

    Carefully:Diabetes mellitus, tuberculosis (systemic damage).
    Pregnancy and lactation:

    The use of Laticort® in pregnant women is allowed in cases when, according to the attending physician, the potential benefit for a pregnant woman prevails over the possible risk to the fetus.In these cases, the application should be short and limited to small areas of the skin. It is not recommended to use in the first trimester of pregnancy.

    During breastfeeding, use for a short time on a small surface of the skin and not apply to the skin of the breast.

    Dosing and Administration:

    Outwardly.

    Have of adults: a small amount of drug applied na.porazhennuyu skin 1-3 times a day. The course of treatment is 1-3 weeks. The dose of the drug used during the week should not exceed 30-60 g. To improve the penetration the drug is applied by massaging movements. In the case of resistance the disease, for example, the localization of dense psoriasis plaques on the elbows, knees, the drug should be used under occlusive dressings.

    Children: Drug use from 6 months of age.

    In childhood, suppression of the function of the adrenal cortex can develop more quickly. In addition, there may be a decrease in the excretion of growth hormone. When using the drug for a long time, it is necessary to observe the body weight, growth, plasma cortisol level. In a pilot study in children who weekly
    30-60 g of Laticort® ointment were obtained, there were no abnormalities of adrenal cortex function.

    When using the drug on the face or under occlusive dressings (diapers, diapers), a greater degree of absorption is possible, so it is recommended to apply a minimal dose of the drug. Treatment should be short-term and under the supervision of a doctor.

    Side effects:

    Side effects are rare and are reversible.

    Local Reactions: rarely - skin irritation.

    With long-term use and / or application to large surfaces, with occlusive dressings, acne-like changes, hypopigmentation, sweating, folliculitis, striae, skin atrophy, hypertrichosis and secondary skin infections are rare in rare cases.

    In rare cases, the development of allergic contact dermatitis.

    Overdose:

    There are no data on the overdose of Latticort® ointment. With prolonged use of the drug in large doses, symptoms of hypercorticism may appear.

    Treatment: symptomatic on the background of a gradual withdrawal of the drug.

    Interaction:

    Data on the drug interaction of the Laticort® ointment with other agents is not available.

    Special instructions:

    Avoid getting Laticourt® ointment in the eyes. If a secondary bacterial or fungal infection develops, an external antibacterial or antifungal agent should be prescribed. With extreme caution, the drug should be applied to the skin of the face due to the possibility of side effects (telangiectasia, atrophy, perioral dermatitis).

    If after 7 days of application there is no improvement or if there is a worsening of the condition, and also if the symptoms recur after a few days after cancellation, the drug should be discontinued and consulted by a doctor.

    Although the use of high doses for long periods, especially when using occlusive dressings may lead to an increase in the content kortazola in blood plasma, it is never accompanied by a decrease in reactivity of the pituitary-adrenal system, and removal of the drug results in a rapid normalization of cortisol production.

    With caution use the drug in cases of already existing atrophic skin conditions, especially in the elderly.

    The risk of side effects is lower than when using halogenated steroids.

    Laticort® ointment is recommended for use in sub-acute inflammatory conditions and lichenification.

    Effect on the ability to drive transp. cf. and fur:The drug does not limit the psychophysical ability, the ability to drive vehicles and maintain machinery in motion.
    Form release / dosage:

    Ointment for external use 0,1%.

    Packaging:

    For 15 grams in aluminum, inside lacquered, lithographed tubes.

    1 tube together with the instruction for use is placed in a cardboard box.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after expiry date.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N012869 / 03
    Date of registration:29.10.2009 / 04.10.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:VALEANT, LLC VALEANT, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspPharmaceutical plant ELPHA A.O. Pharmaceutical plant ELPHA A.O. Poland
    Information update date: & nbsp12.03.2018
    Illustrated instructions
      Instructions
      Up